Sutro Biopharma Inc expected to post a loss of $2.22 a share - Earnings Preview

Sutro Biopharma

03/08/2026 12:13

Sutro Biopharma Inc STRO.OQ STRO.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The South San Francisco California-based  company is expected to report a 79.7% decrease in revenue to $12.953 million from $63.75 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of $2.22 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Sutro Biopharma Inc is $50.00, about 106.9% above its last closing price of $24.17
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-3.72
-3.77
-2.94
Beat
22
Dec. 31 2026
-4.74
-4.34
-5.29
Missed
-21.8
Sep. 30 2025
-4.07
-4.14
-6.70
Missed
-61.7​
Jun. 30 2025
-4.07
-4.02
-1.40
Beat
65.2
​​Mar. 31 2025
-6.96
-7.07
-9.10
Missed
-28.6
Dec. 31 2024
-7.81
-8.31
-8.90
Missed
-7.1​
Sep. 30 2024
-7.29
-7.35
-5.90
Beat
19.7
Jun. 30 2024
-7.60
-7.92
-5.90
Beat
25.5
This summary was machine generated August 3 at 11:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)